Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is genuine scientific interest in whether semaglutide might affect mood, but the current evidence does not support using Wegovy as a treatment for depression, and it is not licensed for that purpose. What researchers have observed is more nuanced: some people on semaglutide report feeling better in themselves as they lose weight, while a separate strand of pharmacology research explores whether GLP-1 receptors in the brain could have independent mood-relevant effects. Neither finding means Wegovy treats depression. It remains a prescription-only medicine for weight management, assessed individually by a prescriber — not a self-prescribed mood supplement.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The link between GLP-1 medicines and mood didn't come from a single dramatic finding. It emerged gradually as participants in large weight-loss trials completed quality-of-life questionnaires. In the STEP 1 trial, published in the New England Journal of Medicine, people taking semaglutide 2.4mg reported improvements in physical functioning and general wellbeing compared with those on placebo. Several participants also noted better sleep, more energy, and reduced emotional distress tied to their weight.
That tells us something real. Carrying significant excess weight affects every dimension of life, mobility, self-image, chronic pain, social confidence. When that burden lifts, a mood improvement follows for many people, entirely independently of anything the drug does in the brain. This is the most important thing to understand when reading headlines about semaglutide and depression. Correlation is not the same as a direct pharmacological effect on mood.
A question our prescribers hear most weeks is whether Wegovy could help someone whose low mood is entangled with their weight, and if you want to look at whether semaglutide helps depression specifically, that question deserves more space than a simple yes or no. The research is live, but it isn't settled. You can explore the full picture on semaglutide as a starting point.
GLP-1 receptors are found not just in the gut and pancreas but in regions of the brain associated with reward processing, appetite signalling and emotional regulation) including the hypothalamus and areas connected to dopamine pathways. Animal studies have shown that GLP-1 receptor activation in the brain can reduce anxiety-like behaviour and attenuate the neurological response to stress. These findings are intriguing enough that researchers are running dedicated trials in humans.
So does Wegovy help with depression at a neurological level? Possibly, in some people, to some degree. But the honest scientific position as of mid-2026 is: we don't know. No large, rigorous randomised controlled trial in humans has established semaglutide as an effective treatment for depression. The evidence base that would justify a licensed indication simply does not exist yet.
What we do know is outlined clearly in the NHS medicines information for semaglutide: Wegovy's licensed use is weight management for adults with a qualifying BMI, alongside a reduced-calorie diet and increased activity. That framing matters clinically. Using a POM outside its evidence base, without a proper assessment, is not safe practice.
The picture isn't uniformly positive. While many people feel better as their weight drops, others report low mood, tearfulness or emotional flatness after starting semaglutide. It's worth being direct about this: mood changes can go in either direction on GLP-1 treatment. The MHRA continues to monitor this through routine Yellow Card reporting, and anyone experiencing significant mood changes, persistent low mood, or thoughts of self-harm on any GLP-1 medicine should seek medical advice promptly rather than waiting for their next review.
For people already living with depression, the calculus is more complex still. Some antidepressants interact with appetite, weight and metabolism, so starting a weight-loss medicine alongside them requires a prescriber who reviews the full clinical picture. This is one reason the question of semaglutide and antidepressants together deserves careful thought rather than a quick yes or no.
There is also a practical question worth raising: if someone's low mood lifts when they lose weight, what happens if treatment eventually stops? Sustainable behavioural change and support alongside any medicine matter here. Wegovy works best as part of a broader effort, not as an isolated fix. The Wegovy treatment overview explains how the medicine fits into a wider plan.
If you're wondering whether Wegovy might help your depression, the most useful thing you can do is have an honest conversation with your GP or a specialist prescriber. Bring both threads: your weight and your mental health history. They are connected for many people, and a prescriber who only addresses one is not serving you fully.
It's also worth reading about whether Wegovy can cause depression and what to watch for, and whether those low-mood episodes tend to resolve as treatment continues. These are real concerns raised by real patients, and the answers are more nuanced than a blanket reassurance would suggest.
For context on what treatment through a regulated online pharmacy involves, including how clinical assessments handle mental health history, our about us page explains how prescribers approach these conversations. If you'd like to explore whether Wegovy is clinically appropriate for you, speaking to our prescribers starts with a free consultation reviewed the same day by a GPhC-registered Independent Prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.